Commercialization

The transplant marketplace is ideally suited for a very small and well-focused selling effort. Transplants are generally performed at a small number of highly specialized centers. For example, in the entire US, transplants are performed at approximately 250 to 280 centers. Patients waiting for a transplant will often travel considerable distances for a transplant at one of these few centers. As such, 20 to 30 sales representatives can cover the majority of these centers. The practice patterns in the European market are comparable with those seen in the US.

Veloxis holds the global rights for LCP-Tacro™ and thus has the potential to commercialize the product either by itself or with partners, both regionally and globally.